The Claim
In non-diabetic adults with overweight or obesity, once-weekly administration of semaglutide at a dose of 2.4 mg results in a mean reduction in waist circumference of 13.5 cm over 68 weeks, which is 9.4 cm greater than the reduction observed with placebo, indicating a significant decrease in abdominal adiposity and associated cardiometabolic risk.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
A weekly shot called semaglutide helped people with extra weight lose nearly 6 inches off their waist over a year and a half, much more than a fake treatment did — which means it may really help reduce belly fat and lower heart and metabolic disease risks.
See the scientific wording
Once-weekly semaglutide at 2.4 mg reduces waist circumference by a mean of 13.5 cm over 68 weeks in non-diabetic adults with overweight or obesity, which is 9.4 cm more than placebo, indicating significant reduction in abdominal adiposity and associated cardiometabolic risk.
What the research says
1 studyStudy: Once-Weekly Semaglutide in Adults with Overweight or Obesity.
The study tested the same drug and dose in similar people and found big weight losses, which usually means smaller waistlines and lower health risks, so it supports the claim even if it didn’t measure waist size exactly.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.